GC Labs

What GC Labs does

GC Labs (의료법인 녹십자의료재단, Medical Corporation Green Cross Medical Foundation) is South Korea's oldest commercial clinical reference laboratory, founded in 1982 as Green Cross Bio Science Lab and rebranded to its current identity in 2012. The organization operates as a medical corporation (의료법인) within the GC Group (Green Cross Corporation / GC Biopharma) family of companies, with headquarters in Yongin, Gyeonggi-do, and serves hospitals, clinics, and pharmaceutical companies nationwide through two main divisions — a Medicine Center and a Pathology Center — plus regional facilities in the Yeongnam (Yangsan) and Honam (Gwangju) areas that were completed in September 2024.

The company's technical platform spans Total Laboratory Automation (TLA) for pre- to post-analytical workflows, the first domestic WASPLab Microbiology Automation deployment, tandem mass spectrometry (including proprietary newborn screening methods), molecular pathology platforms (PCR, sequencing, FISH, SISH), immunohistochemistry, and a digital pathology system under construction. It holds a broad accreditation stack — CAP, ISO 15189, NGSP Level 1 for HbA1c, CDC VDSCP and HoSt certifications, ISO 9001/14001, G-EQUAS, and ISBER — and offers approximately 5,000 test items spanning clinical chemistry, hematology, immunology, microbiology, molecular genetics, pathology, allergy, toxicology, and therapeutic drug monitoring, processing roughly 53,000 specimens per day domestically.

GC Labs monetizes through contract-based diagnostic testing referrals from medical institutions (general clinical tests, specialized diagnostics, and anatomical pathology), supplemented by pharmaceutical central laboratory services for clinical trials, IVD clinical performance testing (the first domestic designated institution for this since 2020), and special health examination services. Marketing is anchored in academic channels — IFCC WorldLab, LMCE, Korean Society for Laboratory Medicine participation, peer-reviewed publications — and distribution flows through a direct enterprise sales motion covering a nationwide network of specimen collection centers and dedicated logistics for pickup and delivery. As a founding member of the Global Diagnostics Network, the foundation also participates in cross-border specimen work spanning approximately 75 countries.

Name

GC Labs

Legal name

의료법인 녹십자의료재단

Website

https://gclabs.co.kr

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

501–1,000 employees

Short description

GC Labs is South Korea's oldest commercial clinical reference laboratory, providing approximately 5,000 diagnostic test items to hospitals, clinics, and pharmaceutical clients through automated, accredited testing centers in Yongin, Yeongnam, and Honam.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Clinical laboratory testing
• Anatomic pathology services
• Diagnostic reference testing
• Molecular diagnostics
• Infectious disease testing

Headquarters

HQ city

Yongsin

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Laboratory Testing Services: Provides diagnostic testing services to medical institutions, hospitals, and clinics on a contract basis. Services include general tests, specialized tests, and pathology examinations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

GC Labs operates as a comprehensive clinical laboratory testing organization providing approximately 5,000 diagnostic test items through its Medicine Center, Pathology Center, and regional centers. Services span clinical chemistry, hematology, immunology, microbiology, molecular genetics, and anatomical pathology, supported by Total Laboratory Automation, tandem mass spectrometry, and molecular diagnostics. The organization also operates the Epi-wave infectious disease epidemiology monitoring platform for public health surveillance.

Product overview

GC Labs operates as a comprehensive clinical laboratory testing organization offering approximately 5,000 clinical test items through its main Medicine Center (진검센터) and Pathology Center (병리센터), supplemented by regional centers in Yeongnam and Honam regions. The company's core offerings include specialized diagnostic testing services across clinical chemistry, hematology, immunology, microbiology, molecular genetics, and anatomical pathology. Additionally, GC Labs provides the Epi-wave infectious disease epidemiology monitoring platform, which offers public-facing dashboards for respiratory infections, influenza surveillance, and gastrointestinal infections. The organization also conducts clinical research testing and provides consulting services for international laboratory setup and operations.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Testing Services Comprehensive clinical laboratory testing services including approximately 5,000 test items covering clinical chemistry, hematology, immunology, microbiology, molecular genetics, and specialized testing areas such as allergy, toxicology, and drug monitoring. Services are provided on a referral basis to hospitals, clinics, and medical institutions across South Korea.
• Anatomic Pathology Services Anatomic pathology reference testing services including histopathology, immunohistochemistry, molecular pathology (PCR, sequencing, FISH, SISH) for cancer diagnosis and drug sensitivity prediction. Services are provided through a dedicated Pathology Center with digital pathology system capabilities.
• Epi-wave Infectious Disease Epidemiology Platform Digital platform providing public-facing dashboards for monitoring respiratory infections, influenza surveillance, and gastrointestinal infections. Enables disease pattern detection and outbreak monitoring for public health agencies and medical institutions.
• Clinical Research Testing Services Central laboratory services for clinical trials, providing standardized, high-quality testing for pharmaceutical companies and research institutions conducting clinical studies. Includes companion diagnostics central lab capabilities through partnerships such as with QIAGEN.

Quantifiable outcome

• Processing 53,000 specimens daily
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• InpecocoreTechnology or Integration · 1 January 2025MOU signed for comprehensive strategic cooperation including pathology laboratory automation equipment introduction.
• QuantMatrixmajorStrategic or Co-development Partner · 1 January 2022Joint infectious disease research partnership.
• KOFIH (Korea International Health Foundation)majorStrategic or Co-development Partner · 1 January 2022Operating KOFIH's Lee Jong-wook Fellowship infectious disease response expert training program for developing countries.
• QIAGEN Manchester LimitedmajorTechnology or Integration · 1 January 2021Companion diagnostics central lab program (DAY-ONE LAB READINESS) partnership.
• KNCV Tuberculosis FoundationmajorStrategic or Co-development Partner · 1 January 2021Partnership for tuberculosis elimination activities.
• MBD Co.minorStrategic or Co-development Partner · 1 January 2021MOU for anticancer drug sensitivity diagnostic testing business using organoid solutions.
• Ewha Womans UniversityminorStrategic or Co-development Partner · 1 January 2019Industry-academia collaboration agreement for talent development.
• Global Diagnostics Network (GDN)coreStrategic or Co-development Partner · 1 January 2018GC Labs is a founding member of the Global Diagnostics Network, a strategic alliance of major diagnostic laboratories worldwide including Quest Diagnostics (USA), Dasa (Brazil), Life Labs (Canada), Synlab (Germany), Al Borg (Saudi Arabia), and others covering 75 countries with access to 300 million patients annually.
• Seoul National University HospitalminorStrategic or Co-development Partner · 1 January 2018Joint research MOU for diagnostic development.
• Dankook University HospitalminorStrategic or Co-development Partner · 1 January 2017Clinical trial joint research MOU.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• LifeLabs: Canadian clinical laboratory and GDN founding member. Directly comparable as a hospital-facing reference testing provider operating within the same global network alliance.
• Al Borg Medical Laboratories: Middle East–headquartered clinical reference lab and GDN founding member. Comparable as a hospital-facing diagnostics provider with similar broad test menus and GDN integration.
• Seoul Clinical Laboratories (SCL / GC Labs affiliate GCCL): Korean clinical reference laboratory operating within the GC Group family. Direct competitor in Korean hospital reference testing and clinical trial central lab services, with overlapping customer base and accreditations.
• Quest Diagnostics: US-headquartered clinical reference laboratory and GDN founding member. Directly comparable as a global clinical lab providing routine and esoteric testing to hospitals and physicians; shares the GDN platform with GC Labs.
• Synlab: European clinical reference laboratory and GDN founding member. Direct comparable as a multi-country reference lab operator serving hospitals with broad test menus and central lab services for clinical trials.
• Dasa: Brazilian diagnostics operator and GDN founding member. Comparable as a regional clinical reference lab providing routine and specialty testing to hospitals, with GDN cross-border referral access.

Broad incumbents

• Laboratory Corporation of America (Labcorp): US-headquartered global clinical laboratory incumbent. Comparable as a broad-based reference testing provider with deep specialty diagnostics, central lab, and clinical trial services.
• BML: Japan-based clinical reference laboratory. Comparable as a large Asian hospital-facing reference testing provider with broad test menu and central lab capabilities.
• SRL (SRL Medisearch): Japan-based major clinical reference laboratory. Comparable as a large Asian hospital-facing reference lab with broad specialty testing, including central lab services for clinical trials.

Regional players

• Eone Diagnomics Genome Center: Korean molecular diagnostics and genome analysis provider. Comparable as a Korean specialty diagnostics player competing in molecular and genetic testing adjacencies to GC Labs' molecular pathology offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC4dbE66nBgDfsKu5h13RVyg
• Facebookfacebook.com/GCLabs.global
• LinkedInlinkedin.com/company/gc-labs

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GC Labs